Home > Business > Sir Graham Brady MP appointed to the board of Medannex

Sir Graham Brady MP appointed to the board of Medannex

Added: (Thu Feb 01 2024)

Pressbox (Press Release) - Medannex strengthens its board ahead of clinical expansion

Medannex Ltd (Edinburgh) announced today that Sir Graham Brady has been appointed as a non-executive director of the company as of 1 February 2024.

Currently a Member of Parliament at Westminster, Sir Graham has had a remarkable political career, having held a range of senior positions. The post for which he is perhaps best known is as the longstanding Chair of the 1922 Committee. He will stand down as an MP at the next general election and plans to devote his time to helping the growth of British business. Sir Graham brings a wealth of experience to Medannex as the company embarks on an ambitious programme of clinical trials.

Sir Graham said: “I am delighted to be joining the team of this young and exciting life sciences company. Medannex has won awards for its pioneering work in areas of unmet medical need and I look forward to being an active part of its continued progress. The UK is looking to companies like Medannex for the next phase of our country’s growth.”

Professor Christopher Wood, Medannex’s Chairman, added: “It’s a real pleasure to welcome Sir Graham to the board of directors of Medannex. He adds a new and important dimension to the company in its quest to develop new treatments for cancer and autoimmune diseases.”

Medannex has a new, first-in-class medicine (MDX-124) currently undergoing clinical trials at three major cancer centres in the UK. MDX-124 has the potential to offer significant clinical benefit in the treatment of many cancers - including pancreas, triple-negative breast, colorectal and lung - as well as autoimmune diseases such as multiple sclerosis, systemic lupus and rheumatoid arthritis. MDX-124 also has potential as a treatment for certain childhood cancers, an opportunity that the company is exploring in the UK and the USA.

Medannex CEO Ian Abercrombie said: ‘”In Medannex we are developing a new treatment with huge potential, and with a magnificent and dedicated team to make it happen. The addition of a board member with the stature of Sir Graham Brady is a tremendous encouragement to the team and our shareholders.”

-

About Medannex Ltd: Medannex is a clinical-stage Scottish biopharmaceutical company headquartered in Edinburgh. The company is developing novel treatments for various cancers, autoimmune diseases and other conditions: https://medannex.org

About MDX-124: MDX-124 is a humanised monoclonal antibody, and the first agent to specifically target and inhibit annexin-A1, a protein known to play a key role in the development of cancers, autoimmune diseases and other conditions. A first in human clinical study (‘ATTAINMENT’) is underway. The FDA has granted MDX-124 Orphan Designation for the treatment of pancreatic cancer, which is the third most common cause of cancer-related death in the US (American Cancer Society, 2022) and therefore represents a significant unmet clinical need. MDX-124 was also awarded Orphan Medicinal Product positive opinion from the European Medicines Agency (EMA) as well as an Innovation Passport as part of the Innovative Licencing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

About the ‘ATTAINMENT’ clinical study: The ‘ATTAINMENT’ study is a modular, multi-arm, first in human study to evaluate the safety and tolerability of MDX-124, alone and in combination with established anti-cancer treatments, in participants with locally advanced, unresectable or metastatic solid malignancies.

- ENDS -

Submitted by:James Ingham
Disclaimer: Pressbox disclaims any inaccuracies in the content contained in these releases. If you would like a release removed please send an email to remove@pressbox.com together with the url of the release.